Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Thromb Haemost ; 112(5): 981-91, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25077916

ABSTRACT

Controlling platelet granule secretion has been considered an effective strategy to dampen thrombosis and prevent atherosclerosis. Anthocyanins are natural plant pigments and possess a wide range of biological activities, including cardiovascular protective activity. In the present study we explored the effects and the potential mechanisms of anthocyanins on platelet granule secretion in hypercholesterolemia. In a randomised, double-blind clinical trial, 150 hypercholesterolaemic individuals were treated with purified anthocyanins (320 mg/day) or placebo for 24 weeks. Anthocyanins consumption significantly reduced plasma levels of ß-thromboglobulin (ß-TG), soluble P-selectin, and of Regulated on Activation Normal T cell Expressed and Secreted (RANTES) as compared with the placebo. A minor reduction in platelet factor 4 (PF4) and transforming growth factor ß1 (TGF-ß1) levels were also observed. In in vitro experiments, we observed that puriÓ¿ed anthocyanin mixture, as well as its two main anthocyanin components, delphinidin-3-glucoside (Dp-3-g) and cyanidin-3-glucoside (Cy-3g) directly inhibited platelet á-granule, dense granule, and lysosome secretion evaluated by P-selectin, RANTES, ß-TG, PF4, TGF-ß1, serotonin, ATP, and CD63 release. Further, anthocyanins inhibited platelet PI3K/Akt activation and consequently attenuated eNOS phosphorylation and cGMP production, thus interrupting MAPK activation. LY294002, a PI3K inhibitor, did not cause additional inhibitory efficacy, indicating that anthocyanin-induced effects may be involved in inhibition of the PI3K/Akt signalling pathway. These results provide evidence that by inhibiting platelet granule secretion, anthocyanins may be a potent cardioprotective agent.


Subject(s)
Anthocyanins/therapeutic use , Blood Platelets/drug effects , Cardiotonic Agents/therapeutic use , Hypercholesterolemia/drug therapy , Phosphatidylinositol 3-Kinases/physiology , Phytotherapy , Proto-Oncogene Proteins c-akt/physiology , Signal Transduction/drug effects , Adenosine Triphosphate/metabolism , Adult , Anthocyanins/pharmacology , Blood Platelets/metabolism , Blood Proteins/metabolism , Cardiotonic Agents/pharmacology , Cytoplasmic Granules/metabolism , Double-Blind Method , Female , Glucosides/pharmacology , Glucosides/therapeutic use , Humans , Hypercholesterolemia/blood , Intercellular Signaling Peptides and Proteins/metabolism , Lysosomes/metabolism , MAP Kinase Signaling System/drug effects , Male , Middle Aged , Phosphorylation/drug effects , Protein Processing, Post-Translational/drug effects
2.
PLoS One ; 7(5): e37323, 2012.
Article in English | MEDLINE | ID: mdl-22624015

ABSTRACT

Delphinidin-3-glucoside (Dp-3-g) is one of the predominant bioactive compounds of anthocyanins in many plant foods. Although several anthocyanin compounds have been reported to be protective against cardiovascular diseases (CVDs), the direct effect of anthocyanins on platelets, the key players in atherothrombosis, has not been studied. The roles of Dp-3-g in platelet function are completely unknown. The present study investigated the effects of Dp-3-g on platelet activation and several thrombosis models in vitro and in vivo. We found that Dp-3-g significantly inhibited human and murine platelet aggregation in both platelet-rich plasma and purified platelets. It also markedly reduced thrombus growth in human and murine blood in perfusion chambers at both low and high shear rates. Using intravital microscopy, we observed that Dp-3-g decreased platelet deposition, destabilized thrombi, and prolonged the time required for vessel occlusion. Dp-3-g also significantly inhibited thrombus growth in a carotid artery thrombosis model. To elucidate the mechanisms, we examined platelet activation markers via flow cytometry and found that Dp-3-g significantly inhibited the expression of P-selectin, CD63, CD40L, which reflect platelet α- and δ-granule release, and cytosol protein secretion, respectively. We further demonstrated that Dp-3-g downregulated the expression of active integrin αIIbß3 on platelets, and attenuated fibrinogen binding to platelets following agonist treatment, without interfering with the direct interaction between fibrinogen and integrin αIIbß3. We found that Dp-3-g reduced phosphorylation of adenosine monophosphate-activated protein kinase, which may contribute to the observed inhibitory effects on platelet activation. Thus, Dp-3-g significantly inhibits platelet activation and attenuates thrombus growth at both arterial and venous shear stresses, which likely contributes to its protective roles against thrombosis and CVDs.


Subject(s)
Anthocyanins/pharmacology , Cardiovascular Diseases/prevention & control , Gene Expression Regulation/drug effects , Glucosides/pharmacology , Platelet Activation/drug effects , Thrombosis/prevention & control , AMP-Activated Protein Kinases/metabolism , Analysis of Variance , Animals , Bleeding Time , CD40 Ligand/metabolism , Flow Cytometry , Humans , In Vitro Techniques , Mice , Mice, Inbred C57BL , P-Selectin/metabolism , Phosphorylation/drug effects , Tetraspanin 30/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...